Research programme: cancer vaccines - immatics biotechnologies/Roche

Drug Profile

Research programme: cancer vaccines - immatics biotechnologies/Roche

Alternative Names: Colorectal cancer ImmunoBody vaccines - immatics/Scancell; Gastric cancer vaccine - immatics; IMA 930; IMA 942; IMA 962; Non-small cell lung cancer vaccine - immatics; TUMAP-based cancer vaccines - immatics/Roche

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator immatics biotechnologies GmbH
  • Developer immatics biotechnologies GmbH; Roche
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer; Non-small cell lung cancer
  • Research Prostate cancer

Most Recent Events

  • 11 Jan 2018 The cancer vaccines programme in collaboration with Roche is still in preclinical development for Non-small cell cancer, Gastric cancer and prostate cancer in Germany (Immatics Biotechnology pipeline, January 2018)
  • 28 Dec 2017 No recent reports of development identified for research development in Prostate-cancer in Germany (Intradermal, Injection)
  • 26 Jun 2017 Scancell has patent protection for DNA ImmunoBody® platform technology in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top